Skip to main content
Premium Trial:

Request an Annual Quote

Ono Pharma Licenses Genedata's Software for Proteomics and Metabolomics Research


Genedata said last week that Ono Pharmaceutical has licensed its Genedata Expressionist for Mass Spectrometry solution and that the Japanese firm would use the tool in its proteomics and metabolomics research efforts.

Ono develops drugs for cancer and cardiovascular diseases. Its research requires "accurate mass profiling analysis as well as powerful [multiple reaction monitoring] capabilities for effective quantitative analysis," a spokesperson for Ono's Tsukuba Research Institute said in a statement.

Genedata's platform, the representative said, is able to integrate data from a variety of instruments and is able to identify clinically relevant biomarkers.

Genedata is not disclosing the financial details of the licensing agreement.